Head-to-head · WeighScore
Eden vs Gala Health
By GLP-1 ScorecardUpdated
Score comparison
Gala Health has the higher recorded score — 82.9/100 to 81.6/100, but only just.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Gala offers low advertised injection prices and a branded Ozempic path, but its campaign and longer-term plan pages need to be reconciled before paying. Eden is close behind and may still be the better fit — see the factor split below.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Eden | Gala Health |
|---|---|---|
| WeighScore | 81.6/100 | 82.9/100 |
| Grade | B− | B− |
| Site position | #16 | #12 |
| Semaglutide | Advertised $99/mo bundle; linked membership terms conflict—confirm checkout | From $129/mo (campaign; plan pages conflict—confirm billing term) |
| Tirzepatide | Advertised $129/mo bundle; linked membership terms conflict—confirm checkout | From $179/mo (campaign; yearly and three-month offers conflict—confirm term) |
| Coverage | All 50 states | Coverage wording differs: all 50 on homepage, most U.S. states in campaign |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #16 · B−
FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.
Strengths
- Current compounded offer includes medication and support
- Homepage also advertises branded prescription pathways; eligibility and cost require confirmation
- Named pharmacy operation and partner network can be investigated
What to consider
- Linked membership terms describe a separate fee model
- Landing-page warranty and terms use different thresholds and conditions
- FDA warning history remains relevant; a new offer does not establish resolution
Site position #12 · B−
Strengths
- Campaign advertises $129 semaglutide and $179 tirzepatide with medication and telehealth visits included if prescribed
- Brand-name Ozempic path and broader menopause/HRT services listed
- Terms identify clinical practice networks; actual clinician and pharmacy assignment still need checking
What to consider
- Yearly, three-month and no-contract campaign presentations differ; do not assume an annual upfront charge or flat month-to-month terms
- Cancel at least 72 hours before renewal; ordinary cancellation does not produce a refund
- Medical-disqualification refund wording differs between full-refund and remaining/current-cycle provisions
- Dispensing pharmacy not identified for an individual order; oral option is a waitlist, not a current offer
Featured provider
Gala Health
Gala Health scores 82.9/100 (B−). Gala offers low advertised injection prices and a branded Ozempic path, but its campaign and longer-term plan pages need to be reconciled before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.